(Q33892010)

29 July 2017

Magnesium oxide augmentation of verapamil maintenance therapy in mania (English)

1 reference

29 July 2017

1 reference

Giannini AJ

1

1 reference

29 July 2017

Nakoneczie AM

2

1 reference

29 July 2017

Melemis SM

3

1 reference

29 July 2017

Ventresco J

4

1 reference

29 July 2017

Condon M

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

93

1 reference

29 July 2017

83-87

1 reference

29 July 2017

1

1 reference

[Indications for the use of magnesium in anesthesia and intensive care]

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Calcium-activated potassium conductance. An alternative to the dopamine hypothesis of neuroleptic action?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Effectiveness of verapamil in the treatment of a manic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

The Na,K-ATPase hypothesis for manic-depression. I. General considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Antimanic effects of verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Comparison of antimanic efficacy of clonidine and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Verapamil and lithium in maintenance therapy of manic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Treatment of mania: relationship between response to verapamil and changes in plasma calcium and magnesium levels

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Do Calcium Antagonists Have a Place in the Treatment of Mood Disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Verapamil in affective disorders: a controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Verapamil therapy for stable and unstable angina pectoris: Calcium channel antagonists in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Neurotoxicity caused by lithium-verapamil synergism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

The calcium messenger system (1).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Calcium-antagonist drugs. Receptor interactions that clarify therapeutic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Superiority of Lithium Over Verapamil in Mania

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

Effects of Nicergoline on Calcium and Magnesium Deposition in the Central Nervous System Tissues of Rats Maintained on Low-Calcium Diets

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900116-X

7 January 2021

10.1016/S0165-1781(99)00116-X

Identifiers

DOI

1 reference

29 July 2017

1 reference